CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...

Dolby Laboratories (DLB) has disclosed a new risk, in the Corporate Activity and Growth category. Dolby Laboratories faces significant business ...

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

Dolby Laboratories, Inc. ( NYSE:DLB ) investors will be delighted, with the company turning in some strong numbers ...

Dolby Laboratories (DLB) reported $357 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 13.1%. EPS of $1.14 for the same period compares to $1.01 a ...

Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive partnerships.

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus ...

Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...

1 Day DLB 1.72% DJIA 0.65% S&P 500 -1.46% Media/Entertainment -0.68% ...